TALS TALARIS THERAPEUTICS INC

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference

Fireside chat date: Monday, September 12, 2022

Fireside chat time: 1:40 p.m. ET

Location: Sheraton Hotel, New York, NY

H.C. Wainwright 24th Annual Global Investment Conference

Presentation date: Wednesday, September 14, 2022

Presentation time: 9:00 a.m. ET

Location: Lotte New York Palace Hotel, New York, NY

A live webcast of the presentations will be available on the investors section of the Talaris website at After the live webcast, a replay of the events can be found on the Talaris website.

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Media Contact

Lisa Raffensperger

Ten Bridge Communications



(617) 903-8783

Investor Contact

Chris Brinzey

ICR Westwicke



(339) 970-2843



EN
06/09/2022

Underlying

TALSTALARIS THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TALARIS THERAPEUTICS INC

 PRESS RELEASE
Free
TALS TALARIS THERAPE...

Talaris Therapeutics Announces Stockholder Approval of Merger with Tou...

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio Combined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris’ stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris’ common stock to the stockholders of Tourmaline Bio,...

October 17, 2023 1 EN
 PRESS RELEASE
Free
TALS TALARIS THERAPE...

Talaris Therapeutics Declares Special Dividend In Connection with Prop...

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Tourmaline Bio, Inc. (“Tourmaline”) pursuant to the Agreement and Plan of M...

October 6, 2023 1 EN
 PRESS RELEASE
Free
TALS TALARIS THERAPE...

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) Combined company expected to have approximately $210 million of cash at the transaction close, including approximately $75 million from a concurrent private placement with leading life sciences investors Strong balance sheet expected to support three clinical trials for TOUR006 including a Phase 2b trial i...

June 22, 2023 1 EN
 PRESS RELEASE
Free
TALS TALARIS THERAPE...

Talaris Therapeutics Announces Leadership Transition

Talaris Therapeutics Announces Leadership Transition BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. , today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris’s Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. “On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and ...

May 26, 2023 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 44.66
EW EDWARDS LIFESCI...
TTWO Take-Two Intera... ... (+31)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

EW EDWARDS LIFESCIENCES CORP
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SKYW SKYWEST INC
RCKY ROCKY BRANDS
PCRX PACIRA BIOSCIENCES INC.
MKC MCCORMICK & COMPANY INCORPORATED
MDT MEDTRONIC PLC
HCI HCI GROUP INC.
ECL ECOLAB INC.
DVA DAVITA INC.
DGX QUEST DIAGNOSTICS INCORPORATED
CHH CHOICE HOTELS INTERNATIONAL INC.
ARWR ARROWHEAD PHARMACEUTICALS INC.
AEE AMEREN CORPORATION
SHW SHERWIN-WILLIAMS COMPANY
BRO BROWN & BROWN INC.
ITKA ANHEUSER-BUSCH INBEV N.V. ADS
SCWX SECUREWORKS
WDFC WD-40 COMPANY
ABT ABBOTT LABORATORIES
FOR FORESTAR GROUP INC.
EVRG EVERGY INC.
DELL DELL TECHNOLOGIES INC CLASS C
GLT GLATFELTER CORPORATION
ZNTL ZENTALIS PHARMACEUTICALS
SWBI SMITH & WESSON BRANDS INC.
SANA SANA BIOTECHNOLOGY
TALS TALARIS THERAPEUTICS INC
FOA FINANCE OF AMERICA COMPANIES INC
TNYA TENAYA THERAPEUTICS INC
HIPO HIPPO HLDGS INC
04/26/23 April 26, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch